Hence, LSD1 inhibitors (e.g., ORY-1001) and histone deacetylase (HDAC) inhibitors such as pracinostat have demonstrated potential in preclinical models by downregulating ASCL1 and suppressing tumor growth [41,70,71]. The gene discussed is ASCL1; the disease is neoplasm.